Nanoneurotherapeutics approach intended for direct nose to brain delivery

Md S 1 , Mustafa G 2 , Baboota S 3 , Ali J 3

Affiliations 

  • 1 a Department of Pharmaceutical Technology , School of Pharmacy, International Medical University (IMU) , Kuala Lumpur , Malaysia
  • 2 b College of Pharmacy, Al-Dawadmi Campus, Shaqra University , Riyadh , Kingdom of Saudi Arabia , and
  • 3 c Faculty of Pharmacy, Department of Pharmaceutics , Jamia Hamdard, New Delhi , India
Drug Dev Ind Pharm, 2015;41(12):1922-34.
PMID: 26057769 DOI: 10.3109/03639045.2015.1052081

Abstract

Brain disorders remain the world's leading cause of disability, and account for more hospitalizations and prolonged care than almost all other diseases combined. The majority of drugs, proteins and peptides do not readily permeate into brain due to the presence of the blood-brain barrier (BBB), thus impeding treatment of these conditions.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications